Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5824830 | Clinical Therapeutics | 2015 | 25 Pages |
Abstract
Results from numerous Phase 3 clinical trials indicate that sofosbuvir- and simeprevir-containing regimens are highly effective and safe for the treatment of chronic hepatitis C infection. The approval of these 2 agents has led to a complete overhaul of published guidelines, with sofosbuvir- and simeprevir-containing regimens included in preferred regimens.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Lindsey M. PharmD, MPH, BCPS, Elizabeth O. PharmD, BCPS,